

Are your MRI contrast agents cost-effective?

Learn more about generic Gadolinium-Based Contrast Agents.



FRESENIUS
KABI

caring for life

AJNR

Pretreatment DWI with Histogram Analysis of the ADC in Predicting the Outcome of Advanced Oropharyngeal Cancer with Known Human Papillomavirus Status Treated with Chemoradiation

This information is current as of April 19, 2024.

M. Ravanelli, A. Grammatica, M. Maddalo, M. Ramanzin, G.M. Agazzi, E. Tononcelli, S. Battocchio, P. Bossi, M. Vezzoli, R. Maroldi and D. Farina

AJNR Am J Neuroradiol 2020, 41 (8) 1473-1479

doi: <https://doi.org/10.3174/ajnr.A6695>

<http://www.ajnr.org/content/41/8/1473>

Pretreatment DWI with Histogram Analysis of the ADC in Predicting the Outcome of Advanced Oropharyngeal Cancer with Known Human Papillomavirus Status Treated with Chemoradiation

M. Ravanelli, A. Grammatica, M. Maddalo, M. Ramanzin, G.M. Agazzi, E. Tononcelli, S. Battocchio, P. Bossi, M. Vezzoli, R. Maroldi, and D. Farina

ABSTRACT

BACKGROUND AND PURPOSE: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased in the period from the 1970s to 2004, due to increase of infection with human papilloma virus (HPV). This study aimed to examine the role of histogram analysis of the ADC in treatment response and survival prediction of patients with oropharyngeal squamous cell carcinoma and known human papillomavirus status.

MATERIALS AND METHODS: This was a retrospective single-center study. Following inclusion and exclusion criteria, data for 59 patients affected by T2–T4 (according to the 8th edition of the *AJCC Cancer Staging Manual*) oropharyngeal squamous cell carcinoma were retrieved. Twenty-eight had human papillomavirus–positive oropharyngeal squamous cell carcinoma, while 31 had human papillomavirus–negative oropharyngeal squamous cell carcinoma. All patients underwent a pretreatment MR imaging. Histogram analysis of ADC maps obtained by DWI ($b = 0\text{--}1000\text{ mm}^2/\text{s}^2$) was performed on the central section of all of tumors. The minimum follow-up period was 2 years. Histogram ADC parameters were associated with progression-free survival and overall survival. Univariable and multivariable Cox models were applied to the data; P values were corrected using the Benjamini-Hochberg method.

RESULTS: At univariable analysis, both human papillomavirus status and mean ADC were associated with progression-free survival (hazard ratio = 0.267, $P < .05$, and hazard ratio = 1.0028, $P \leq .05$, respectively), while only human papillomavirus status was associated with overall survival (hazard ratio = 0.213, $P \leq .05$) before correction. At multivariable analysis, no parameter was included (in fact, human papillomavirus status lost significance after correction). If we separated the patients into 2 subgroups according to human papillomavirus status, ADC entropy was associated with overall survival in the human papillomavirus–negative group (hazard ratio = 4.846, $P = .01$).

CONCLUSIONS: ADC and human papillomavirus status are related to progression-free survival in patients treated with chemoradiation for advanced oropharyngeal squamous cell carcinoma; however, this association seems to result from the strong association between ADC and human papillomavirus status.

ABBREVIATIONS: HPV = human papillomavirus; OPSCC = oropharyngeal squamous cell carcinoma; OS = overall survival; PFS = progression-free survival; TNM = Tumor, Node, Metastasis

In the United States, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased from the 1970s to 2004,¹ despite successful effort to control alcohol and tobacco abuse. The increase is due to the increasing incidence of OPSCC related to infection with Human Papillomavirus (HPV), in particular,

among younger men who did not smoke or consume alcohol excessively.

Along with the increasing incidence of OPSCC, survival rates have improved. In fact, HPV-related OPSCC is a separate entity compared with HPV-negative OPSCC, with different biologic behavior and better outcome. Thus, HPV-positive and HPV-negative OPSCC have 2 distinct Tumor, Node, Metastasis (TNM) systems in the 8th edition of the *AJCC Cancer Staging Manual*,^{2–4} and dose de-intensification protocols for HPV-positive OPSCC are being investigated in clinical trials.⁵

HPV status has, thus, become one of the most important factors in predicting survival in patients with OPSCC. However, several methods are being investigated to better stratify the risk of

Received February 4, 2020; accepted after revision May 23.

From the Departments of Radiology (M. Ravanelli, M. Ramanzin, G.M.A., E.T., R.M., D.F.), Otorhinolaryngology (A.G.), Radiation Oncology (M.M.), Pathological Anatomy (S.B.), and Medical Oncology (P.B.), and Molecular and Translational Medicine (M.V.), University of Brescia, Brescia, Italy.

Please address correspondence to Marco Ramanzin, MD, Department of Radiology, University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy; e-mail: marco.ramanzin91@gmail.com

<http://dx.doi.org/10.3174/ajnr.A6695>

treatment failure.^{6,7} The predictive nomograms obtained from these studies, including clinical, social, and educational variables, have proved valid in the geographic context in which they were developed but are not replicable in populations with different geographic provenances.⁸ Thus, more objective biomarkers or surrogates are required to predict response to treatment and survival and to build more reproducible models.

Radiomics is a “big data” approach based on the extraction of several quantitative features from diagnostic images (mainly CT images), which are then used to build predictive and prognostic models. Leijenaar et al⁹ developed and externally validated a CT radiomics signature for predicting survival in patients with OPSCC without taking into account other clinicopathologic data, HPV included. The M.D. Anderson Cancer Center Head and Neck Quantitative Imaging Working Group developed a CT-based radiomics signature, which, together with HPV status, age, sex, and smoking status, predicted survival (unfortunately, HPV status was not known in more than half of the patients).¹⁰

Radiomics is currently a complex and computationally expensive approach, and further studies are needed to translate these into clinical scenarios. Furthermore, all of these studies are based on CT images, while in some centers, MR imaging is used to more accurately stage OPSCC. At the present time, no radiomics studies based on MR imaging have been performed in this setting.

DWI is an MR imaging sequence that explores tissue microarchitecture, relying on water motion within it, which is quantitatively described by the ADC. This sequence is currently part of most of the standard protocols in head and neck cancer studies.

As will be discussed later in more detail, ADC has been used as a potential predictor of outcome in head and neck cancer.¹¹ However, in these studies, relevant tumor characteristics have usually been omitted, hampering the clinical utility of their results. ADC maps can be easily segmented and expressed as a mean value or, in more detail, described by first-order statistics (histogram analysis).

This study aimed to ascertain the role of ADC histogram analysis in the treatment response and survival prediction of patients with OPSCC with known HPV status.

The hypothesis that gives origin to this study is that the role of ADC in patient stratification is overestimated when HPV status is not known; the latter (whose predictive role is well-established) is strongly associated with the former.

MATERIALS AND METHODS

Patients

This was a single-center retrospective study including patients with histologically proved T2–T4 OPSCC who underwent chemoradiation with curative intent after an individual assessment performed by our internal multidisciplinary team. Patients were enrolled between March 2010 and April 2017 to guarantee a minimum 2-year follow-up period. Inclusion criteria were the following: patients with pretreatment head and neck MR imaging with sufficient image quality and in whom echo-planar DWI sequences were acquired; tumors with known HPV status; and smoking

status. We excluded patients with low-quality MR images because of motion artifacts (nondiagnostic, as assessed by an expert head and neck radiologist); tumors too small to be segmented (<2 cm); and patients with <2 years of follow-up in whom recurrence or death had not occurred. Staging was calculated for each patient according to the 8th edition of *AJCC Cancer Staging Manual*, Head and Neck Section.

HPV Determination

HPV status was determined with the *digene* Hybrid Capture 2 High-Risk HPV DNA test (Qiagen). This is an in vitro nonradioactive nucleic acid hybridization assay with signal amplification using a chemiluminescent microtiter plate. This test is able to detect 18 HPV types, including high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and low-risk types (6, 11, 42, 43, 44). The Hybrid Capture 2 test (Qiagen) shows a sensitivity and specificity equivalent to that of the polymerase chain reaction. DNA analysis was performed independent from p16/INK4a status, which was also assessed.

Chemoradiation Therapy

Patients were treated with definitive radiochemotherapy, delivered with a linear accelerator using an intensity-modulated technique (intensity-modulated radiotherapy, volumetric modulated arc therapy, or TomoTherapy [SSMHealth]). In the case of conventional fractionation with sequential boost, a dose of 70 Gy was prescribed to the tumor and the lymph nodes involved, while a dose of 50 Gy was prescribed to the remaining uninvolved neck levels. In case of treatment planned with a simultaneous integrated boost, slight variations in the number of fractions, total dose, and dose per fraction were administered, with doses equivalent to normo-fractionation. Chemotherapy with concurrent cisplatin was administered weekly at a dose of 40 mg/m².

MR Imaging Protocol

MR imaging studies were performed on a 1.5T scanner (Magnetom Aera; Siemens) with a dedicated head and neck 20-channel phased array coil. The acquisition protocol included the following: T2-weighted TSE sequences on axial and coronal planes (for palatine tonsil cancer) or the sagittal plane (for base of the tongue and posterior wall cancers); a T1-weighted TSE sequence on the axial plane; a 3D fat-saturated gradient recalled-echo sequence (volumetric interpolated brain examination) with isotropic spatial resolution of 0.7 mm after gadolinium-based contrast agent injection; and DWI with the following parameters: TR = 3900 ms, TE 5 = 9 ms, section thickness = 3 mm, matrix = 132 × 132, b-values = 0 and 1000 mm/s². The ADC was generated automatically. Treatment response was assessed with a second MR imaging study performed 12 weeks after treatment (Fig 1).

Image Analysis

T2-weighted TSE sequences and DWI sequences with ADC maps were transferred to an off-line PC and analyzed using open-source software (ImageJ; National Institutes of Health). The segmentation was performed by a head and neck radiologist with >10 years' experience. An ROI encompassing the whole primary tumor on its largest cross-sectional area was




FIG 1. Axial T2, $b = 1000$, and ADC map of an OPSCC of the right palatine tonsil.

Table 1: Baseline patient and tumor characteristics

	Total ($n = 59$)	HPV+ ($n = 28$)	HPV- ($n = 31$)	P Value
Age (yr)	66.3	66.2	67.4	.9
Sex				
Male	43	19	24	.41
Female	16	9	7	
Smoker	34/59	8/28	26/31	<.0001
Site	38, Palatine tonsil 17, Tongue base 3, Soft palate 1, Posterior wall	20, Palatine tonsil 7, Tongue base 1, Soft palate	18, Palatine tonsil 10, Tongue base 2, Soft palate 1, Posterior wall	.61
TNM classification				
T	T2 = 25 T3 = 2 T4 = 32	T2 = 16 T3 = 1 T4 = 11	T2 = 9 T3 = 1 T4 = 21 (16, T4a; 5, T4b)	.08
N	N0 = 14 N1 = 15 N2 = 18 N3 = 12	N0 = 7 N1 = 13 N2 = 6 N3 = 2	N0 = 7 N1 = 2 N2 = 12 (8, N2b; 4, N2c) N3 = 10 (N3b = 10)	.002
M	M0 = 57 M1 = 2	M0 = 27 M1 = 1	M0 = 30 M1 = 1	.14

Note:—HPV+ indicates human papillomavirus–positive; HPV–, human papillomavirus–negative.

drawn on ADC maps; the segmentation was aided using side-by-side visualization of T2-weighted and $b = 1000$ images. We calculated the following histogram parameters on ADC maps: mean, SD, kurtosis, skewness, and entropy. “Kurtosis” indicates the histogram peakedness (the lower the kurtosis, the more flattened the histogram); “skewness” is related to histogram symmetry (positive skewness indicates a right-tailed histogram); and “entropy” is a metric positively associated with image heterogeneity.

Statistical Analysis

Descriptive statistics were used to summarize patient and tumor characteristics. Cox proportional hazards regression was used for survival analysis. Univariate analysis was used first, and parameters with significant P values in univariable analysis were used as independent variables in the multivariate analysis. Kaplan-Meier curves were used to graphically display survival in different subgroups. The primary end point was progression-free survival (PFS; recurrence or death was considered to be a dependent event); the secondary end point was overall survival (OS; death from any cause was considered to be a dependent event). Finally,

logistic regression between the histogram parameter of ADC and HPV status was conducted to assess whether any association was present between ADC parameters and HPV. All P values were corrected to minimize the false discovery rate (Benjamini-Hochberg correction).

Statistical significance was fixed at $P < .05$. Statistical analysis was performed using MedCalc 16.4.3 (MedCalc Software).

RESULTS

Patient and Tumor Characteristics

In total, 68 patients with T2–T4 OPSCC were included according to the inclusion criteria. Of those, 4 patients were excluded because the primary tumor was too small to be segmented; a further 5 patients were excluded because of low image quality due to motion artifacts, as established by an expert head and neck radiologist. Analysis was thus performed on 59 patients (43 men, 16 women). Baseline patient and tumor characteristics are shown in Table 1. Notably, 28 patients had HPV-positive tumors, while 31 had an HPV-negative lesion. Eight of the 28 HPV-positive patients were smokers, while the incidence rose to 26/31 patients with HPV-negative tumors ($P > .0001$).

Image Characteristics and Survival Analysis

Seventeen patients died during the follow-up, while 10 were alive with progression at 2-year follow-up.

As shown in an earlier study, the mean ADC was significantly lower in HPV-positive patients compared with HPV-negative ones (P value < .001).¹² HPV status and ADC were the only parameters significantly correlated with PFS in univariate analysis, and only HPV status remained significantly associated with PFS in the multivariate analysis, even if it lost significance after correction for the false discovery rate. Only HPV status was associated with OS (Table 2); it also lost significance after correction. Kaplan-Meier curves were plotted for PFS (Fig 2) and OS (Fig 3) using HPV status as a dichotomic variable and for PFS with a mean ADC split by its median value (Fig 4).

At multivariate analysis, only HPV status maintained a statistically significant association with PFS, even if it lost its significance after the Benjamini-Hochberg correction (Table 2). Conversely, the mean ADC was not significantly associated with survival, meaning that the association between ADC and HPV status masked the significance of HPV as a unique independent factor related to survival.

Table 2: Univariable analysis for PFS and OS

	HR	95% CI	P Value	Corrected P Value
PFS, univariate analysis				
HPV	0.27	0.11–0.67	.01	.03
Mean ADC (961.37 ± 184)	1.00	1.00–1.00	.01	.03
SD ADC (186.64 ± 54.32)	1.00	0.9966–1.0115	.29	.44
Kurtosis ADC (2.08 ± 2.17)	1.08	0.87–1.34	.50	.50
Skewness ADC (0.86 ± 0.76)	0.81	0.45–1.45	.48	.50
Entropy ADC (184 ± 0.5)	1.90	0.78–4.67	.16	.32
OS, univariate analysis				
HPV	0.21	0.06–0.76	.02	.10
Mean ADC	1.00	0.999–1.004	.2	.34
SD ADC	0.1	0.985–1.005	.34	.34
Kurtosis ADC	1.15	0.89–1.15	.3	.34
Skewness ADC	0.69	0.35–1.35	.28	.34
Entropy ADC	2.75	0.9–8.43	.08	.23

Note:—HR indicates hazard ratio.




FIG 2. Kaplan-Meier curve showing better progression-free survival in the HPV-positive group (*P* value, log-rank test < .0001).




FIG 3. Kaplan-Meier curve showing better overall survival in the HPV-positive group (*P* value, log-rank test < .0001).

When we divided the cohort into 2 subgroups according to HPV status, none of the ADC variables were associated with survival, apart from ADC entropy, which was associated with OS in HPV-negative patients (*P* value = .015) (Table 3).

DISCUSSION

It is now broadly accepted that diffusion-weighted imaging can predict outcome in head and neck tumors treated with chemoradiation. In particular, high ADC values are correlated with poor outcome. The explanation for this association is that high ADC is correlated with lower cell density (reflecting lower cell proliferation), a higher stromal component, and intratumor micronecrosis.^{13,14} Studies that correlate ADC with treatment response usually consider heterogeneous cohorts of patients affected by head and neck cancer, even though a significant portion is represented by patients with OPSCC. A summary of these studies, the prevalence of OPSCC in those studies, and the influence of ADC on outcome are reported in Table 4.¹⁵⁻²⁸

All of these studies, apart from one,²⁸ have an important limitation, that of not considering HPV as a covariate in survival analysis. As already mentioned, the role of HPV status in prognostication of treatment response and survival outcome in patients with OPSCC has unquestionably been established.

Some studies found a correlation between ADC and HPV status in patients with OPSCC.^{12,28-31} De Perrot et al³² correlated ADC histogram parameters with HPV status and other histologic features in 105 patients. In a well-balanced cohort of patients, Ravanelli et al¹² demonstrated that lower ADC is associated with positive HPV status. This result is explained by the higher cellularity of these tumors related to a high infiltration of leukocytes, which are characterized by a very low nucleus-to-cytoplasm ratio, thus resulting in inter- and intracellular water motility.

This study represents the continuation of the above-mentioned study. After a follow-up of at least 2 years, as




FIG 4. Kaplan-Meier curve showing better progression-free survival in the group with ADC lower than the median value (P value, log-rank test $< .0001$).

Table 3: Survival analysis for PFS and OS, dividing the group on the basis of HPV status

ADC	HPV-Positive P Value	HPV-Negative P Value
DFS		
Mean (961.37 ± 184)	.27	.40
SD (186.64 ± 54.32)	.79	.79
Kurtosis (2.08 ± 2.17)	.17	.98
Skewness (0.86 ± 0.76)	.53	.79
Entropy (184 ± 0.5)	.63	.24
OS		
Mean	.14	.37
SD	.24	.13
Kurtosis	.57	.14
Skewness	.06	.65
Entropy	.19	.01 ^a

Note:—DFS indicates disease-free survival.

^aOR = 4.8461; 95% CI, 1.3507–17.3868.

expected, a positive correlation was found between outcome and HPV status. Moreover, in line with the cited literature, a negative correlation of ADC with disease-free survival was found in the univariate analysis. Other histogram parameters calculated on ADC maps did not correlate with survival in the global group of patients; however, when a multivariate analysis was performed considering mean ADC and HPV status as covariates, only the latter variable maintained its association with survival (however, it was lost after correction to minimize the false discovery rate). The explanation for this result seems to be quite straightforward: The variable with true correlation with outcome is HPV status, while the influence of ADC is likely due to its correlation with HPV status.

When we separated HPV-positive and HPV-negative patients into distinct subgroups, the mean ADC did not correlate with survival. In the univariate analysis, only ADC entropy correlated ($P = .01$) with survival in the HPV-negative group. Even if, at the moment, the small sample size might cast some doubt on the credibility of this result, it could be hypothesis-generating research for a larger sample size of HPV-negative tumors.

Table 4: Studies investigating the relationship between pretreatment ADC and outcome after chemoradiation therapy in head and neck cancer

Reference	Year of Publication	No. of Patients	No. of Patients with OPSCC	HPV Status Available	High ADC Associated with
Kim et al ¹⁵	2009	33	22	N	Poor outcome
Hatakenaka et al ¹⁶	2011	57	22	N	Poor outcome
Ohnishi et al ¹⁷	2011	64	30	N	Poor outcome
Srinivasan et al ¹⁸	2012	20	11	N	Poor outcome
Nakajo et al ¹⁹	2012	26	8	N	Better outcome
King et al ²⁰	2013	37	14	N	Poor outcome
Chawla et al ²¹	2013	32	9	N	Poor outcome
Lambrecht et al ²²	2014	161	85	N	Poor outcome
Ng et al ²³	2016	69	37	N	Poor outcome
Noij et al ²⁴	2015	78	40	N	Poor outcome
Preda et al ²⁵	2016	57	11	N ^a	Poor outcome
Marzi et al ²⁶	2017	34	14	N/Y ^b	Poor outcome
Lombardi et al ²⁷	2017	47	19	N	Poor outcome
Martens et al ²⁸	2019	134	96	Y	Poor outcome ^c

Note:—N indicates no; Y, yes.

^aMinimum ADC value within the ROI.

^bOnly for the small cohort of patients with OPSCC.

^cMaximum ADC value within the ROI.

Recently, Martens et al²⁸ published a well-organized article using ADC histogram analysis to predict HPV status and patient outcome. In agreement with our results, they found a significantly lower ADC value in HPV-positive lesions (P value < .001). On the other hand, they found that the maximum value of ADC within lesions was negatively correlated with outcome, independent of HPV status and TNM (P = .024). They hypothesized that areas of high ADC could reflect intratumoral necrosis, which is associated with a poorer prognosis. Unlike their study, we have not calculated the maximum ADC; furthermore, they did not find any correlation between outcome and mean ADC, which was a strong predictor of disease-free survival in our study.

Even though they cannot be easily compared with other studies, our results may provide new insights and permit a critical evaluation of previous results. Furthermore, our results demonstrate that OPSCC should be considered a separate entity in studies involving diffusion-weighted imaging as a possible biomarker for outcome prediction, and knowledge of HPV status is mandatory to provide reliability.

Our study has some limitations. First, its retrospective design did not allow some potentially relevant clinical or laboratory variables to be collected. Second, the sample size, even though comparable with that of other literature studies, was low. Third, a study of power to detect the correct number of patients to be enrolled has not been performed. Fourth, ADC was measured on a single central section, which may not be fully representative of the whole tumor.

CONCLUSIONS

This study demonstrates that ADC is related to disease-free survival after chemoradiation in patients affected by advanced OPSCC. However, this correlation seems to result from the strong association between ADC and HPV status, the latter representing a well-known predictor of survival. Because of these findings, the role of DWI in stratification of OPSCC and, more generally, of head and neck cancer should be revised and likely underestimated. These findings could permit a critical revision of the previous literature and the design of future studies aimed at testing diffusion-weighted imaging as a biomarker of survival in these patients.

Disclosures: Marco Ravanelli—RELATED: Payment for Writing or Reviewing the Manuscript; Linguistic Editing; UNRELATED: Payment for Manuscript Preparation; Linguistic Editing. Paolo Bossi—RELATED: Consulting Fee or Honorarium; UNRELATED: Consultancy; Galera Therapeutics, Comments: less than €1500. Davide Farina—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus; Marco Ravanelli 2019, Comments: around €1000; Payment for Development of Educational Presentations: Bracco 2020, Comments: around €1000.

REFERENCES

1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. **Human papillomavirus and rising oropharyngeal cancer incidence in the United States.** *J Clin Oncol* 2011;29:4294–4301 [CrossRef Medline](#)
2. Huang SH, O'Sullivan B. **Overview of the 8th Edition TNM Classification for Head and Neck Cancer.** *Curr Treat Options Oncol* 2017;18:40 [CrossRef Medline](#)
3. Würdemann N, Wagner S, Sharma SJ, et al. **Prognostic impact of AJCC/UTCC 8th Edition new staging rules in oropharyngeal squamous cell carcinoma.** *Front Oncol* 2017;7:129 [CrossRef Medline](#)
4. Zanoni DK, Patel SG, Shah JP. **Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of Head and Neck Cancer: rationale and implications.** *Curr Oncol Rep* 2019;21:52 [CrossRef Medline](#)
5. Windon MJ, D'Souza G, Fakhry C. **Treatment preferences in human papillomavirus-associated oropharyngeal cancer.** *Future Oncol* 2018;14:2521–30 [CrossRef Medline](#)
6. Larsen CG, Jensen DH, Carlander AL, et al. **Novel nomograms for survival and progression in HPV+ and HPV– oropharyngeal cancer: a population-based study of 1,542 consecutive patients.** *Oncotarget* 2016;7:71761–72 [CrossRef Medline](#)
7. Fakhry C, Zhang Q, Nguyen-Tân PF, et al. **Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer.** *J Clin Oncol* 2017;35:4057–65 [CrossRef Medline](#)
8. Bossi P, Miceli R, Granata R, et al. **In reply to Fakhry et al.** *Int J Radiat Oncol Biol Phys* 2018;102:670–71 [CrossRef Medline](#)
9. Leijenaar RT, Carvalho S, Hoebbers FJ, et al. **External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma.** *Acta Oncol* 2015;54:1423–29 [CrossRef Medline](#)
10. M.D. Anderson Cancer Center Head and Neck Quantitative Imaging Working Group. **Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients.** *Sci Rep* 2018;8:1524 [CrossRef Medline](#)
11. King AD, Thoeny HC. **Functional MRI for the prediction of treatment response in head and neck squamous cell carcinoma: potential and limitations.** *Cancer Imaging* 2016;16:23 [CrossRef Medline](#)
12. Ravanelli M, Grammatica A, Tononcelli E, et al. **Correlation between human papillomavirus status and quantitative MR imaging parameters including diffusion-weighted imaging and texture features in oropharyngeal carcinoma.** *AJNR Am J Neuroradiol* 2018;39:1878–83 [CrossRef Medline](#)
13. Driessen JP, Caldas-Magalhaes J, Janssen LM, et al. **Diffusion-weighted MR imaging in laryngeal and hypopharyngeal carcinoma: association between apparent diffusion coefficient and histologic findings.** *Radiology* 2014;272:456–63 [CrossRef Medline](#)
14. Swartz JE, Driessen JP, van Kempen PM, et al. **Influence of tumor and microenvironment characteristics on diffusion-weighted imaging in oropharyngeal carcinoma: a pilot study.** *Oral Oncol* 2018;77:9–15 [CrossRef Medline](#)
15. Kim S, Loevner L, Quon H, et al. **Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck.** *Clin Cancer Res* 2009;15:986–94 [CrossRef Medline](#)
16. Hatakenaka M, Nakamura K, Yabuuchi H, et al. **Pretreatment apparent diffusion coefficient of the primary lesion correlates with local failure in head-and-neck cancer treated with chemoradiotherapy or radiotherapy.** *Int J Radiat Oncol Biol Phys* 2011;81:339–45 [CrossRef Medline](#)
17. Ohnishi K, Shioyama Y, Hatakenaka M, et al. **Prediction of local failures with a combination of pretreatment tumor volume and apparent diffusion coefficient in patients treated with definitive radiotherapy for hypopharyngeal or oropharyngeal squamous cell carcinoma.** *J Radiat Res* 2011;52:522–30 [CrossRef Medline](#)
18. Srinivasan A, Chenevert TL, Dwamena BA, et al. **Utility of pretreatment mean apparent diffusion coefficient and apparent diffusion coefficient histograms in prediction of outcome to chemoradiation in head and neck squamous cell carcinoma.** *J Comput Assist Tomogr* 2012;36:131–37 [CrossRef Medline](#)
19. Nakajo M, Nakajo M, Kajiya Y, et al. **FDG PET/CT and diffusion-weighted imaging of head and neck squamous cell carcinoma: comparison of prognostic significance between primary tumor standardized uptake value and apparent diffusion coefficient.** *Clin Nucl Med* 2012;37:475–80 [CrossRef Medline](#)
20. King AD, Chow KK, Yu KH, et al. **Head and neck squamous cell carcinoma: diagnostic performance of diffusion-weighted MR imaging for the prediction of treatment response.** *Radiology* 2013;266:531–38 [CrossRef Medline](#)

21. Chawla S, Kim S, Dougherty L, et al. **Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck.** *AJR Am J Roentgenol* 2013;200:35–43 [CrossRef Medline](#)
22. Lambrecht M, Van Calster B, Vandecaveye V, et al. **Integrating pretreatment diffusion weighted MRI into a multivariable prognostic model for head and neck squamous cell carcinoma.** *Radiother Oncol* 2014;110:429–34 [CrossRef Medline](#)
23. Ng SH, Liao CT, Lin CY, et al. **Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.** *Eur Radiol* 2016;26:4162–72 [CrossRef Medline](#)
24. Noij DP, Pouwels PJ, Ljumanovic R, et al. **Predictive value of diffusion-weighted imaging without and with including contrast-enhanced magnetic resonance imaging in image analysis of head and neck squamous cell carcinoma.** *Eur J Radiol* 2015;84:108–16 [CrossRef Medline](#)
25. Preda L, Conte G, Bonello L, et al. **Combining standardized uptake value of FDG-PET and apparent diffusion coefficient of DW-MRI improves risk stratification in head and neck squamous cell carcinoma.** *Eur Radiol* 2016;26:4432–41 [CrossRef Medline](#)
26. Marzi S, Piludu F, Sanguineti G, et al. **The prediction of the treatment response of cervical nodes using intravoxel incoherent motion diffusion-weighted imaging.** *Eur J Radiol* 2017;92:93–102 [CrossRef Medline](#)
27. Lombardi M, Cascone T, Guenzi E, et al. **Predictive value of pretreatment apparent diffusion coefficient (ADC) in radio-chemotherapy treated head and neck squamous cell carcinoma.** *RadiolMed* 2017;122:345–52 [CrossRef Medline](#)
28. Martens RM, Noij DP, Koopman T, et al. **Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.** *Eur J Radiol* 2019;113:39–50 [CrossRef Medline](#)
29. Chan MW, Higgins K, Enepekides D, et al. **Radiologic differences between human papillomavirus-related and human papillomavirus-unrelated oropharyngeal carcinoma on diffusion-weighted imaging.** *ORL J Otorhinolaryngol Relat Spec* 2016;78:344–52 [CrossRef Medline](#)
30. Nakahira M, Saito N, Yamaguchi H, et al. **Use of quantitative diffusion-weighted magnetic resonance imaging to predict human papilloma virus status in patients with oropharyngeal squamous cell carcinoma.** *Eur Arch Otorhinolaryngol* 2014;271:1219–25 [CrossRef Medline](#)
31. Schouten CS, de Graaf P, Bloemena E, et al. **Quantitative diffusion-weighted MRI parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.** *AJNR Am J Neuroradiol* 2015;36:763–67 [CrossRef Medline](#)
32. de Perrot T, Lenoir V, Domingo Ayllón M, et al. **Apparent diffusion coefficient histograms of Human Papillomavirus-positive and human papillomavirus-negative head and neck squamous cell carcinoma: assessment of tumor heterogeneity and comparison with histopathology.** *AJNR Am J Neuroradiol* 2017;38:2153–60 [CrossRef Medline](#)